883984-95-0Relevant articles and documents
NOVEL HETEROCYCLIC COMPOUNDS AND USE THEREOF IN MEDICINE AND IN COSMETICS
-
Paragraph 1392, (2018/03/25)
The invention relates to novel heterocyclic compounds of general formula (I), as well as their pharmaceutically acceptable salts, and their enantiomers. The invention also relates to the use thereof as a medicinal product, preferably in the prevention and/or treatment of inflammatory diseases with a neurogenic component or use thereof as a cosmetic. The compounds of the present invention act as antagonists of the CGRP-R receptor.
NOVEL COMPOUNDS
-
Page/Page column 45-46, (2011/02/18)
The present invention relates to new CGRP-antagonists of general formula I wherein U, V, X, Y, R1, R2, R3 and R4 are defined as in the description, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates, the mixtures thereof and the salts thereof and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, medicaments containing these compounds, their use and processes for preparing them.
Optimization of azepanone calcitonin gene-related peptide (CGRP) receptor antagonists: Development of novel spiropiperidines
Burgey, Christopher S.,Potteiger, Craig M.,Deng, James Z.,Mosser, Scott D.,Salvatore, Christopher A.,Yu, Sean,Roller, Shane,Kane, Stefanie A.,Vacca, Joseph P.,Williams, Theresa M.
scheme or table, p. 6368 - 6372 (2010/05/02)
Several novel spiropiperidine-based CGRP receptor antagonists have been developed that maintain good potency and have reduced potential for metabolism.